Endpoints and assessments
nonsquamous, PD‐L1, death, Cancer
DISEASE PROGRESSION, ADVERSE EVENT, ADVERSE EVENT, DISEASE, SECONDARY, SQUAMOUS CELL CARCINOMA, DISEASE, CANCER
Disease assessments using RECIST version 1.1The primary endpoint was ORR as determined via investigator assessments according to RECIST version 1.1.The secondary endpoints were disease control rate (DCR), PFS, which is the time from the date of enrollment to the date of disease progression, OS, which is the time from the date of enrollment to the date of death from any cause, and safety. Adverse events were evaluated in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0.In subset analyses, we examined ORR, PFS, and OS by age, sex, ECOG performance status, histological type (nonsquamous or squamous cell carcinoma), history of smoking (current smoking, past smoking or non‐smoking), the degree of PD‐L1 expression, and number of previous regimens.